SCHEMBL8237015

SCHEMBL8237015

CCCC(=O)NCC(N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFPT1 Q06210 1/20 0.46
CTSD P07339 1/20 0.45
CASP2 P42575 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NOD1 Q9Y239 2/20 0.41
SLC1A2 P43004 4/20 0.41
SLC1A1 P43005 4/20 0.41
SLC1A3 P43003 3/20 0.41
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
DDAH1 O94760 1/20 0.41
NOS1 P29475 1/20 0.41
P2RY10 O00398 1/20 0.40
GPR174 Q9BXC1 1/20 0.40
PSMB5 P28074 1/20 0.39
SLC7A5 Q01650 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16860714 0.89 NOD1 (0.49) GFPT1NOD1SLC1A2SLC1A1SLC1A3
SCHEMBL8237369 0.89 NOD1 (0.49) GFPT1NOD1SLC1A2SLC1A1SLC1A3
SCHEMBL29215257 0.87 NOD1 (0.55) NOD1SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL16860735 0.87 NOD1 (0.55) NOD1SLC1A2SLC1A1GRIK1GRIK2
SCHEMBL25284318 0.85 NOD1 (0.57) NOD1GRIK1GRIK2P2RY10GPR174
SCHEMBL8240378 0.85 NOD1 (0.57) NOD1GRIK1GRIK2P2RY10GPR174
SCHEMBL29875541 0.85 NOD1 (0.57) NOD1GRIK1GRIK2P2RY10GPR174
SCHEMBL25052917 0.85 NOD1 (0.57) NOD1GRIK1GRIK2P2RY10GPR174
SCHEMBL16860733 0.85 NOD1 (0.57) NOD1GRIK1GRIK2P2RY10GPR174
SCHEMBL29215585 0.85 NOD1 (0.57) NOD1GRIK1GRIK2P2RY10GPR174

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576175-B2 Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-08-18 US disclosed
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy ITGA4, ITGB4, ITGA1 GFPT1 728/4885CTSD 3452/4885CASP2 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.